This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Investors Undervaluing Tenet Healthcare (THC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
If You Invested $1000 in Tenet Healthcare 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Here's Why Tenet Healthcare (THC) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Tenet Healthcare (THC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Rising Expenses Hurt Acadia Healthcare's Q1 Earnings?
by Zacks Equity Research
ACHC's first-quarter results are likely to reflect benefits from growing revenue per patient day.
Is Trending Stock Tenet Healthcare Corporation (THC) a Buy Now?
by Zacks Equity Research
Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Lower Expenses Save Pediatrix Medical's Q1 Earnings?
by Zacks Equity Research
MD's first-quarter results are likely to reflect declining hospital contract administrative fees.
Zacks.com featured highlights Fox, Universal Technical Institute, Pfizer, Tenet Healthcare and Newmont
by Zacks Equity Research
Fox, Universal Technical Institute, Pfizer, Tenet Healthcare and Newmont have been highlighted in this Screen of The Week article.
Despite Fast-paced Momentum, Tenet (THC) Is Still a Bargain Stock
by Zacks Equity Research
Tenet (THC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
If You Invested $1000 in Tenet Healthcare a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Fox (FOXA), Universal Technical Institute (UTI), Pfizer (PFE), Tenet Healthcare (THC) and Newmont (NEM) are likely to beat on the bottom line in their upcoming releases.
Tenet Beats Q1 Earnings on Strong Ambulatory Unit, Ups '25 EPS View
by Zacks Equity Research
THC's first-quarter results benefit on the back of higher net revenue per case and the expansion of service lines within the Ambulatory Care unit. It currently expects 2025 adjusted EPS within $11.99-$13.12.
Why Tenet Healthcare (THC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tenet (THC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tenet Healthcare (THC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 40.19% and 1.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health Services and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Tenet Healthcare, Universal Health Services and Community Health Systems have been highlighted in this Industry Outlook article.
Doctor's Orders: 4 Hospital Stocks to Benefit From Industry Trends
by Kaibalya Pravo Dey
The Zacks Medical-Hospital industry is likely to gain from growing demand, improving operating stability and finances. Companies like HCA, THC, UHS and CYH are poised to benefit from these trends.
Stay Ahead of the Game With Tenet (THC) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Tenet (THC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Tenet Healthcare (THC) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Tenet Healthcare (THC) closed at $122.10, indicating a -1.72% shift from the previous trading day.
All You Need to Know About Tenet (THC) Rating Upgrade to Buy
by Zacks Equity Research
Tenet (THC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Tenet Healthcare (THC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts Think Tenet (THC) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Tenet (THC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
HCA Healthcare (HCA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 11.79% and 0.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.